3D Mol Similar

Methyldopa

Iupac Name：(2S)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid

CAS No.: 555-30-6

Molecular Weight：211.21452

Modify Date.: 2022-11-12 07:12

Introduction: It is prescribed for arterial hypertension and hypertensive crises. View more+

Request For Quotation

1. Names and Identifiers

1.1 Name: Methyldopa
1.2 Synonyms: (&minus)-3-(3,4-Dihydroxyphenyl)-2-methyl-L-alanine sesquihydrate (-)-3-(3,4-Dihydroxyphenyl)-2-Methyl-L-Alanine Sesquihydrate (-)-Methyldopa (-)-α-Methyldopa (2S)-2-Amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid (S)-(-)-a-Methyldopa (S)-a-Methyldopa 2-METHYL-3-(3,4-DIHYDROXYPHENYL)ALANINE 3-(3,4-Dihydroxyphenyl)-2-methyl-L-alanine,MK-351,Methyl-L-DOPA 3-(3,4-Dihydroxyphenyl)-α-methyl-L-alanine 3-Hydroxy-α-methyl-L-tyrosine 3-Hydroxy-α-methyltyrosine hydrate (1:1) Alanine, 3- (3,4-dihydroxyphenyl)-2-methyl-, L- Aldomet ALDORIL Alpha-Methyldopa Sesquihydrate alpha-methyl-L-dopa a-Methyl Dopa a-Methyl-b-(3,4-dihydroxyphenyl)-L-alanine a-Methyl-L-dopa Bayer 1440L Dopamet Dopegyt EINECS 209-089-2 Elanpres L-(-)-a-Methyl-b-(3,4-dihydroxyphenyl)alanine L-(-)-b-(3,4-Dihydroxyphenyl)-a-methylalanine L-(-)-α-Methyl-Β-(3,4-dihydroxyphenyl)alanine L-(a-Md) L-A-METHYL DOPA MK-351, METHYLDOPA L-a-Methyl-3,4-dihydroxyphenylalanine l-a-Methyldopa L-Tyrosine, 3-hydroxy-.alpha.-methyl- L-Tyrosine, 3-hydroxy-α-methyl- L-Tyrosine, 3-hydroxy-α-methyl-, hydrate (2:3) L-α-Methyldopa L-α-Methyl-DOPA Methyl dopa Methyldopa (EDMF/COS) Methyldopa Sesquihydrate MethyldopaUsp28/Bp2003/Ep5 MFCD00004186 Tyrosine, 3-hydroxy-α-methyl-, hydrate (1:1) α-Methyl dopa α-Methyldopa sesquihydrate α-Methyl-L-dopa

1.3 CAS No.: 555-30-6

1.4 CID: 38853

1.5 EINECS(EC#): 209-089-2

1.6 Molecular Formula: C10H13NO4 (isomer)

1.7 Inchi: InChI=1S/C10H13NO4/c1-10(11,9(14)15)5-6-2-3-7(12)8(13)4-6/h2-4,12-13H,5,11H2,1H3,(H,14,15)/t10-/m0/s1

1.8 InChkey: CJCSPKMFHVPWAR-JTQLQIEISA-N

1.9 Canonical Smiles: CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)N

1.10 Isomers Smiles: C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N

2. Properties

2.1 Density: 1.403

2.1 Melting point: 300℃

2.1 Boiling point: 441.6°Cat760mmHg

2.1 Refractive index: -14 ° (C=1, H2O)

2.1 Flash Point: 220.9°C

2.1 Precise Quality: 211.08400

2.1 PSA: 103.78000

2.1 logP: 1.14260

2.1 Solubility: 10g/L(temperature not stated)

2.2 Appearance: Colorless or almost colorless crystals or white to yellowish-white fine powder. Almost tasteless. In the sesquihydrate form.

2.3 Storage: Store at RT

2.4 Color/Form: Minute, anhyd crystals from methanol
WHITE TO YELLOWISH WHITE, FINE POWDER, WHICH MAY CONTAIN FRIABLE LUMPS

2.5 Decomposition: When heated to decomposition it emits toxic fumes of nitroxides.

2.6 Odor: ODORLESS

2.7 PH: pH of saturated aq soln about 5.0

2.8 pKa: 2.28±0.26(Predicted)

2.9 Water Solubility: 10 g/L

2.10 Spectral Properties: Max absorption: 281 nm (e= 2780); Specific optical rotation (1 in 0.1 N HCl): -4.0 +/- 0.5 deg @ 23 deg C/D

2.11 Stability: Stable under normal temperatures and pressures.

2.12 StorageTemp: Sealed in dry,2-8°C

3. Use and Manufacturing

3.1 Definition: ChEBI: A derivative of L-tyrosine having a methyl group at the alpha-position and an additional hydroxy group at the 3-position on the phenyl ring.

3.2 Purification Methods: Recrystallise methyldopa from H2O. [Reinhold et al. J Org Chem 33 1209 1968.] The L-isomer forms a sesquihydrate from H2O m 302-304o (dec), and the anhydrous crystals are hygroscopic,[] 23D -4.0o (c 1, 0.1N HCl), []546 +154.5o (c 5, CuSO4 solution). It has max at 281nm ( 2780). Its solubility in H2O at 25o is ~10mg/mL and the pH of an aqueous solution is ~5.0. It is insoluble in most organic solvents. [Stein et al. J Am Chem Soc 77 700 1955, Beilstein 4 IV 2505.] Methyldopa Preparation Products And Raw materials Raw materials

3.3 Usage: It is prescribed for arterial hypertension and hypertensive crises.

4. Safety and Handling

4.1 Risk Statements: S24/25

4.1 Safety Statements: S24/25

4.1 Exposure Standards and Regulations: Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

4.2 Fire Hazard: Flash point data for Methyldopa are not available; however, Methyldopa is probably combustible.

4.3 DisposalMethods: SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

4.4 Safety Profile: Poison by intraperitoneal route. Moderately toxic by ingestion and intravenous routes. Human systemic effects by ingestion: fasciculations, hallucinations, distorted perceptions, tremors, allergic dermatitis, necrotic gastrointestinal changes. An experimental teratogen. Human reproductive effects: menstrual cycle changes or disorders, effects on newborn including abnormal neonatal measures and growth statistics, biochemical and metabolic changes. Experimental reproductive effects. Mutation data reported. When heated to decomposition it emits toxic fumes of NOx

4.5 Formulations/Preparations: METHYLDOPA, USP (ALDOMET), IS AVAILABLE FOR ORAL ADMIN IN TABLETS CONTAINING 125, 250, OR 500 MG. MORE SOL PREPN, METHYLDOPATE HYDROCHLORIDE, USP (ALDOMET ESTER HYDROCHLORIDE), IS AVAILABLE IN 5-ML VIALS (50 MG/ML) FOR PARENTERAL USE.

4.6 WGK Germany: 3

4.6 RTECS: YP2860000

4.6 Safety: WGK: Germany 3
RTECS :YP2860000
F :10-23

4.7 Specification

Side effects:

?Methyldopa (CAS NO.555-30-6) is capable of inducing a number of adverse side effects, which range from mild to severe. Nevertheless, they are generally mild when the dose is less than 1 gram per day.Side effects may include:

Psychological
Depression and/or even suicidal ideation, as well as nightmares
Apathy and/or anhedonia, as well as dysphoria
Anxiety, especially of the social anxiety variant
Decreased alertness, awareness, and wakefulness
Impaired attention, focus, and concentration

Physiological
Dizziness, lightheadedness, or vertigo
Miosis or pupil constriction
Xerostomia or dry mouth
Gastrointestinal disturbances such as diarrhea and/or constipation
Headache or migraine

4.8 Toxicity

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
man	TDLo	oral	1071mg/kg/22W (1071mg/kg)	SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER SYSTEMIC EXPOSURE"	CUTIS; Cutaneous Medicine for the Practitioner. Vol. 38, Pg. 187, 1986.
mouse	LD50	intraperitoneal	150mg/kg (150mg/kg)	CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION	Journal of Medicinal Chemistry. Vol. 20, Pg. 1378, 1977.
mouse	LD50	intravenous	1700mg/kg (1700mg/kg)	?	Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology. Vol. 56, Pg. 1103, 1960.
mouse	LD50	oral	5300mg/kg (5300mg/kg)	?	Drugs in Japan Vol. -, Pg. 1178, 1990.
rabbit	LD50	intravenous	713mg/kg (713mg/kg)	?	"Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 348, 1972.
rabbit	LD50	oral	713mg/kg (713mg/kg)	?	"Drug Dosages in Laboratory Animals - A Handbook," Rev. ed., Barnes, C.D., and L.G. Eltherington, Berkeley, Univ. of California Press, 1973Vol. -, Pg. 162, 1973.
rat	LD50	intraperitoneal	300mg/kg (300mg/kg)	?	"Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 348, 1972.
rat	LD50	oral	5gm/kg (5000mg/kg)	?	"Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 348, 1972.
women	TDLo	oral	900mg/kg/13W- (900mg/kg)	BEHAVIORAL: TREMOR	Neurology. Vol. 35, Pg. 1668, 1985.
women	TDLo	oral	1830mg/kg/17W (1830mg/kg)	PERIPHERAL NERVE AND SENSATION: FASCICULATIONS BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" BEHAVIORAL: TREMOR	South African Medical Journal. Vol. 65, Pg. 194, 1984.
women	TDLo	oral	44gm/kg/3Y-I (44000mg/kg)	GASTROINTESTINAL: NECROTIC GHANGES	American Heart Journal. Vol. 105, Pg. 1037, 1983.

View all

5. MSDS

2.Hazard identification

2.1 Classification of the substance or mixture

Reproductive toxicity, Category 2

2.2 GHS label elements, including precautionary statements

Pictogram(s)
Signal word	Warning
Hazard statement(s)	H361 Suspected of damaging fertility or the unborn child
Precautionary statement(s)
Prevention	P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P280 Wear protective gloves/protective clothing/eye protection/face protection.
Response	P308+P313 IF exposed or concerned: Get medical advice/ attention.
Storage	P405 Store locked up.
Disposal	P501 Dispose of contents/container to ...

2.3 Other hazards which do not result in classification

none

View all

6. Synthesis Route

555-30-6Total: 13 Synthesis Route

5846-22-0

555-30-6 214 Suppliers

Literatures:
Tetrahedron Letters, , vol. 26, # 40 p. 4957 - 4958
Yield: null

16825-27-7

555-30-6 214 Suppliers

Literatures:
Chemical and pharmaceutical bulletin, , vol. 13, # 12 p. 1399 - 1407
Yield: null

99531-07-4

555-30-6 214 Suppliers

Literatures:
Tetrahedron Letters, , vol. 26, # 40 p. 4957 - 4958
Yield: null

View all

7. Precursor and Product

precursor:

5846-22-0

39948-18-0

109522-07-8

121704-32-3

98262-54-5

99531-07-4

10144-60-2

21852-32-4

111793-95-4

33859-00-6

16825-27-7

111793-96-5

product :

79439-78-4

4821-01-6

6988-74-5

8. Other Information

8.0 Merck: 14,6055

8.1 Target: Value

8.2 Description: Methyldopa is an α-methoxylated derivative of levodopa that exhibits hypotensive action by reducing overall peripheral vascular resistance and reducing heart work. Antihypertensive action of methyldopa consists of the biotransformation of methyldopa into methylnoradrenaline (methylnorepinephrine), which acts as a “pseudo neurotransmitter.” The current, universally accepted point of view is that the action of methyldopa is carried out through the CNS, where methylnorepinephrine, a powerful stimulant of α-adrenergic receptors of the medulla, inhibits the vasomotor center.

8.3 Originator: Aldometil,MSD,W. Germany,1962

8.4 Uses: It is prescribed for arterial hypertension and hypertensive crises.

8.5 Uses: L-(-)-a-Methyldopa is an anti-Parkinson’s drug that has been used in anti-Parkinson’s mixtures.

8.6 Uses: Antihypertensor;L-aromatic aminoacid decarboxylase inhibitor

8.7 Uses: vitamin, coenzyme B12

8.8 Definition: ChEBI: A derivative of L-tyrosine having a methyl group at the alpha-position and an additional hydroxy group at the 3-position on the phenyl ring.

8.9 Manufacturing Process: The dl-α-methyl-3,4-dihydroxyphenylalanine may be made as described in US Patent 2,868,818. Five-tenths of a gram of 3-hydroxy-4- methoxyphenylalaninewas dissolved in 20 ml of concentrated hydrochloric acid, the solution saturated with hydrogen chloride and heated in a sealed tube at 150°C for 2 hours. The dark reaction mixture was concentrated to dryness in vacuo, excess acid removed by flushing several times with ethanol. On dissolving the dark residue in a minimum amount of water and adjusting the clarified solution to pH 6.5 with ammonium hydroxide the compound separated in fine crystals which were filtered, washed with alcohol and ether. The crystalline product had a MP of 299.5 to 300°C with decomposition.
Then, as described in US Patent 3,158,648, the optical isomers may be resolved as follows. 37 g of racemic α-methyl-3,4-dihydroxyphenylalanine are slurried at 35°C in 100 cc of 1.0 N hydrochloric acid. The excess solids are filtered leaving a saturated solution containing 34.6 g of racemic amino acid of which about 61% is present as the hydrochloride. The solution is then seeded at 35°C with 7 g of hydrated L-α-methyl-3,4-dihydroxyphenylalanine (6.2 g of anhydrous material). The mixture is then cooled to 20°C in 30 minutes and aged one hour at 20°C. The separated material is isolated by filtration, washed twice with 10 cc of cold water and dried in vacuo. The yield of product is 14.1 g of L-α-methyl-3,4-dihydroxyphenylalanine in the form of a sesquihydrate of 100% purity as determined by the rotation of the copper complex.

8.10 Therapeutic Function: Antihypertensive

8.11 Biological Functions: The spectrum of activity of α-methyldopa (Aldomet) lies between those of the more potent agents, such as guanethidine, and the milder antihypertensives, such as reserpine. α-Methyldopa is a structural analogue of dihydroxyphenylalanine (dopa) and differs from dopa only by the presence of a methyl group on the -carbon of the side chain.

8.12 General Description: Methyldopa differs structurally from L-DOPA only in the presence of a -methyl group. Originally synthesized as an AADC inhibitor,methyldopa ultimately decreases the concentration of DA,NE, E, and serotonin in the CNS and periphery. However,its mechanism of action is not caused by its inhibition ofAADC but, rather, by its metabolism in the CNS to its activemetabolite ( β-methylnorepinephrine). Methyldopa istransported actively into CNS via an aromatic amino acidtransporter, where it is decarboxylated by AADC in thebrain to (1R,2S)- α-methyldopamine. This intermediate, inturn, is stereospecifically β-hydroxylated by DBH to givethe (1R,2S)-α-methylnorepinephrine. This active metaboliteis a selective α2-agonist because it has correct(1R,2S) configuration . It is currently postulated that α-methylnorepinephrine acts on α2-receptors in theCNS in the same manner as clonidine, to decrease sympatheticoutflow and lower blood pressure.

8.13 General Description: Colorless or almost colorless crystals or white to yellowish-white fine powder. Almost tasteless. In the sesquihydrate form. pH (saturated aqueous solution) about 5.0.

8.14 Air & Water Reactions: Very hygroscopic. Slightly water soluble. May be sensitive to prolonged exposure to air and light. The stability of aqueous solutions is markedly dependent on pH, oxygen and the amount of initial reactant. Aqueous solutions are stable for up to 50 hours in acid and neutral pH (6.2). At pH 8.0, decomposition products are formed in 3 to 5 hours. Solutions develop a red tint that becomes progressively darker (eventually forming a black precipitate).

8.15 Reactivity Profile: Methyldopa undergoes catalytic oxygenation in the presence of magnesium, cupric, cobalt, nickel and ferric ions . A weakly acidic amino acid.

8.16 Fire Hazard: Flash point data for Methyldopa are not available; however, Methyldopa is probably combustible.

8.17 Biological Activity: L-aromatic amino acid decarboxylase inhibitor. Antihypertensive.

8.18 Mechanism of action: A number of theories have been put forward to account for the hypotensive action of α-methyldopa. Current evidence suggests that for α-methyldopa to be an antihypertensive agent, it must be converted to α-methylnorepinephrine; however, its site of action appears to be in the brain rather than in the periphery. Systemically administered α-methyldopa rapidly enters the brain, where it accumulates in noradrenergic nerves, is converted to α-methylnorepinephrine, and is released. Released α-methylnorepinephrine activates CNS α- adrenoceptors whose function is to decrease sympathetic outflow. Why α-methylnorepinephrine decreases sympathetic outflow more effectively than does the naturally occurring transmitter is not entirely clear.

8.19 Pharmacology: The primary hemodynamic alteration responsible for the hypotensive effects of α-methyldopa remains in dispute. When the patient is supine, the reduction in blood pressure produced by α-methyldopa correlates best with a decrease in peripheral vascular resistance, cardiac output being only slightly reduced. When the patient is upright, the fall in blood pressure corresponds more closely with a reduced cardiac output.
An important aspect of α-methyldopa’s hemodynamic effects is that renal blood flow and glomerular filtration rate are not reduced. As occurs with most sympathetic depressant drugs and vasodilators, long-term therapy with α-methyldopa leads to fluid retention, edema formation, and plasma volume expansion.While data conflict somewhat, it is generally thought that - methyldopa suppresses plasma renin activity.

8.20 Pharmacokinetics: The oral bioavailability of methyldopa ranges from 20 to 50% and varies among individuals. Optimum blood pressure response occurs in 12 to 24 hours in most patients. After withdrawal of the drug, blood pressure returns to pretreatment levels within 24 to 48 hours. Methyldopa and its metabolites are weakly bound to plasma proteins. Although 95% of a dose of methyldopa is eliminated in hypertensive patients with normal renal function, with a plasma half-life of approximately 2 hours, in patients with impaired renal function the half-life is doubled to approximately 3 to 4 hours, with about 50% of it excreted. Orally administered methyldopa undergoes presystemic first-pass metabolism in the gastrointestinal (GI) tract to its 3-O-monosulfate metabolite. Sulfate conjugation occurs to a greater extent when the drug is given orally than when it is given intravenously (IV). Its rate of sulfate conjugation is decreased in patients with renal insufficiency. Methyldopa is excreted in urine as its mono-O-sulfate conjugate. Any peripherally decarboxylated α-methylnorepinephrine is metabolized by catecho-o-methyltransferase (COMT) and monoamine oxidase (MAO). Methyldopate is slowly hydrolyzed in the body to form methyldopa. The hypotensive effect of IV methyldopate begins in 4 to 6 hours and lasts 10 to 16 hours.

8.21 Clinical Use: α-Methyldopa is not generally believed to be suitable for monotherapy of primary hypertension. Because plasma volume increases as the duration of α-methyldopa therapy is extended, the drug should be used in conjunction with a diuretic; this will produce a significantly greater fall in blood pressure than would occur with either drug used alone. Because α-methyldopa lowers blood pressure without compromising either renal blood flow or the glomerular filtration rate, it is particularly valuable in hypertension complicated by renal disease. However, if end-stage renal failure accompanies severe hypertension,α-methyldopa may not be effective.
The presence of α-methyldopa and its metabolites in the urine reduces the diagnostic value of urinary catecholamine measurements as an indicator of pheochromocytoma, since these substances interfere with the fluorescence assay for catecholamines.

8.22 Side effects: The most commonly encountered side effects of α- methyldopa are sedation and drowsiness.These CNS effects are probably the result of reductions in brain catecholamine levels. Other side effects, also typical of sympathetic depression, are dry mouth, nasal congestion, orthostatic hypertension, and impotence.
Autoimmune reactions associated with α-methyldopa treatment include thrombocytopenia and leukopenia. Since a few cases of an α-methyldopa–induced hepatitis have occurred, the drug is contraindicated in patients with active hepatic disease. Flulike symptoms also are known to occur.

8.23 Safety Profile: Poison by intraperitoneal route. Moderately toxic by ingestion and intravenous routes. Human systemic effects by ingestion: fasciculations, hallucinations, distorted perceptions, tremors, allergic dermatitis, necrotic gastrointestinal changes. An experimental teratogen. Human reproductive effects: menstrual cycle changes or disorders, effects on newborn including abnormal neonatal measures and growth statistics, biochemical and metabolic changes. Experimental reproductive effects. Mutation data reported. When heated to decomposition it emits toxic fumes of NOx

8.24 Chemical Synthesis: Methyldopa, (-)-3-(3,4-dihydroxyphenyl)-2-methylalanine (22.2.5), is synthesized by a few methods that are only slightly different. The first method is from 3,4- dimethoxyphenylacetone, which undergoes a Strecker–Zelinski reaction using potassium cyanide and ammonium carbonate, to give 4-methyl-4-(3,4-dimethoxybenzylhydantoine (22.3.3), which is further hydrolyzed in the presence of barium hydroxide to give ()-3-(3,4-dimethoxyphenyl)-2-methylalanine (22.3.4). This undergoes acetylation at the amino group, and the racemic mixture is then separated using (-)-1-phenylethylamine. The isolated isomer is hydrolyzed using hydrobromic acid, which simultaneously removes the methoxy- and acetyl groups to give the desired (-)-3-(3,4-dihydroxyphenyl)-2-methylalanine (22.3.5) [8–10]. Alternative syntheses have been proposed.

8.25 Metabolism: Approximately 50% of an orally administered dose of α-methyldopa is absorbed from the gastrointestinal tract. Both peak plasma drug levels and maximal blood pressure–lowering effects are observed 2 to 6 hours after oral administration. A considerable amount of unchanged α-methyldopa and several conjugated and decarboxylated metabolites can be found in the urine.

8.26 Purification Methods: Recrystallise methyldopa from H2O. [Reinhold et al. J Org Chem 33 1209 1968.] The L-isomer forms a sesquihydrate from H2O m 302-304o (dec), and the anhydrous crystals are hygroscopic,[] 23D -4.0o (c 1, 0.1N HCl), []546 +154.5o (c 5, CuSO4 solution). It has max at 281nm ( 2780). Its solubility in H2O at 25o is ~10mg/mL and the pH of an aqueous solution is ~5.0. It is insoluble in most organic solvents. [Stein et al. J Am Chem Soc 77 700 1955, Beilstein 4 IV 2505.]

9. Computational chemical data

Molecular Weight: 211.21452g/mol
Molecular Formula: C₁₀H₁₃NO₄
Compound Is Canonicalized: True
XLogP3-AA: -1.9
Exact Mass: 211.08445790
Monoisotopic Mass: 211.08445790
Complexity: 246
Rotatable Bond Count: 3
Hydrogen Bond Donor Count: 4
Hydrogen Bond Acceptor Count: 5
Topological Polar Surface Area: 104
Heavy Atom Count: 15
Defined Atom Stereocenter Count: 1
Undefined Atom Stereocenter Count: 0
Defined Bond Stereocenter Count: 0
Undefined Bond Stereocenter Count: 0
Isotope Atom Count: 0
Covalently-Bonded Unit Count: 1
CACTVS Substructure Key Fingerprint: AAADccByOAAAAAAAAAAAAAAAAAAAAAAAAAAwAAAAAAAAAAABAAAAHgAQCAAADIyBmAAyDoBAAgCIAiDSCAACAAAgIAAIiAGGiIgLJjKCkROAcAEk0BEJmAeY2PGOIAABAAAAQABAAAIAAACAAAAAAAAAAA==

10. Recommended Suppliers

Global205SuppliersView all >>

Hebei Crovell Biotech Co. Ltd Diamond member

3YRS

Products:Cosmetic Raw Materials,solvents,etc.
Tel:86-311-66562153
Email:sales7@crovellbio.com

Methyldopa

Purity:99%Packing: 200kg/bag FOB
Price: 1 USD/kilogram
Time: 2023/05/30

Inquire

Hebei Fanggan New Material Technology Co., LTD Diamond member

1YR

Products:chemicals
Tel:0311-18503114-031178503114
Email:andy@rilonchem.com

CAS 555-30-6，Methyldopa，99%

Purity:99%Packing: 200kg/bag FOB
Price: 50 USD/kg
Time: 2023/05/30

Inquire

Xiamen wonderful Biotechnology Co., Ltd. Diamond member

1YR

Products:Top quality and high purity with safe transportation and low price
Tel:+86153-92039515-15392039515
Email:victoria@xmwonderfulbio.com

Lower Price Higher Quality Hot Selling cas:555-30-6 Methyldopa Overseas warehouse spot

Purity:99%Packing: 200kg/bag FOB
Price: 20 USD/kg
Time: 2023/05/30

Inquire

Henan Bao Enluo International Trade Co. Ltd Diamond member

1YR

Products:Pharmaceutical intermediates
Tel:173-31933971-17331933971
Email:deasea125996@gmail.com

Methyldopa Sesquihydrate CAS 555-30-6

Purity:99%Packing: 200kg/bag FOB
Price: 10 USD/kg
Time: 2023/05/30

Inquire

Qiaoxi Shengyou Chemical Co., LTD Diamond member

1YR

Products:pharmaceutical intermediates Organic raw materialsAnimal and plant extracts1.4BDO, Eutylone,4MMC, JWH ,SGT Peptide, Steroids, Benzos,Dissociatives
Tel:86-311-18931626169
Email:accountmanager1@yeah.net

Methyldopa

Purity:99%Packing: 200kg/bag FOB
Price: 1 USD/kg
Time: 2023/05/30

Inquire

11. Realated Product Infomation

115217-60-2 Dimethyl methyldopa

41372-08-1 alpha-Methyldopa sesquihydrate

884-39-9 L-(-)-α-Methyldopa (hydrochloride)

5123-53-5 Methyldopa Ethyl Ester HCl

Recently Updated : 173307-16-9 1691833-83-6 159081-26-2 168833-78-1 1936681-09-2 1314938-73-2 154323-59-8 147405-49-0 147405-54-7 147405-42-3